| Literature DB >> 20724536 |
Pavel I Nedvetsky1, Vedrana Tabor, Grazia Tamma, Sven Beulshausen, Philipp Skroblin, Aline Kirschner, Kerim Mutig, Mareike Boltzen, Oscar Petrucci, Anna Vossenkämper, Burkhard Wiesner, Sebastian Bachmann, Walter Rosenthal, Enno Klussmann.
Abstract
Arginine-vasopressin (AVP) modulates the water channel aquaporin-2 (AQP2) in the renal collecting duct to maintain homeostasis of body water. AVP binds to vasopressin V2 receptors (V2R), increasing cAMP, which promotes the redistribution of AQP2 from intracellular vesicles into the plasma membrane. cAMP also increases AQP2 transcription, but whether altered degradation also modulates AQP2 protein levels is not well understood. Here, elevation of cAMP increased AQP2 protein levels within 30 minutes in primary inner medullary collecting duct (IMCD) cells, in human embryonic kidney (HEK) 293 cells ectopically expressing AQP2, and in mouse kidneys. Accelerated transcription or translation did not explain this increase in AQP2 abundance. In IMCD cells, cAMP inhibited p38-mitogen-activated protein kinase (p38-MAPK) via activation of protein kinase A (PKA). Inhibition of p38-MAPK associated with decreased phosphorylation (serine 261) and polyubiquitination of AQP2, preventing proteasomal degradation. Our results demonstrate that AVP enhances AQP2 protein abundance by altering its proteasomal degradation through a PKA- and p38-MAPK-dependent pathway.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20724536 PMCID: PMC3013543 DOI: 10.1681/ASN.2009111190
Source DB: PubMed Journal: J Am Soc Nephrol ISSN: 1046-6673 Impact factor: 10.121